The effectiveness of novel oral antiviral treatment for non-hospitalized high-risk patients with COVID-19 during predominance of omicron XBB subvariants
Objectives This study investigated the association between nirmatrelvir plus ritonavir (NMV-
r) or molnupiravir and the outcomes of non-hospitalized high-risk patients with COVID-19 …
r) or molnupiravir and the outcomes of non-hospitalized high-risk patients with COVID-19 …
The effectiveness of novel oral antiviral treatment for non-hospitalized high-risk patients with COVID-19 during predominance of omicron XBB subvariants
CK Hsu, WH Hsu, BW Shiau, YW Tsai… - Expert review of anti … - pubmed.ncbi.nlm.nih.gov
Objectives This study investigated the association between nirmatrelvir plus ritonavir (NMV-
r) or molnupiravir and the outcomes of non-hospitalized high-risk patients with COVID-19 …
r) or molnupiravir and the outcomes of non-hospitalized high-risk patients with COVID-19 …
The effectiveness of novel oral antiviral treatment for non-hospitalized high-risk patients with COVID-19 during predominance of omicron XBB subvariants.
CK Hsu, WH Hsu, BW Shiau, YW Tsai… - Expert Review of Anti …, 2024 - europepmc.org
Objectives This study investigated the association between nirmatrelvir plus ritonavir (NMV-
r) or molnupiravir and the outcomes of non-hospitalized high-risk patients with COVID-19 …
r) or molnupiravir and the outcomes of non-hospitalized high-risk patients with COVID-19 …